Skip to content

Dose-effect study of tamazepine combined with propofol for painless gastroscopy anesthesia - determination of ED50 and ED95 in different age groups based on the modified Dixon method

Dose-effect study of tamazepine combined with propofol for painless gastroscopy anesthesia - determination of ED50 and ED95 in different age groups based on the modified Dixon method

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124717
Enrollment
Unknown
Registered
2026-05-15
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with digestive system diseases who need painless gastroscopy

Interventions

Youth group 18-44 years old:This study employed the modified Dixon sequential method to measure the half-maximal effective dose of the drug. If the gastroscopy insertion response was positive, the dos
if the gastroscopy insertion response was negative, the dose of the next case of tizoxanide was decreased by one concentration gradient. The case number and dose corresponding to the positive gastrosc
Middle-aged group (45-64 years :This study employed the modified Dixon sequential method to measure the half-maximal effective dose of the drug. If the gastroscopy insertion response was positive, the
if the gastroscopy insertion response was negative, the dose of the next

Sponsors

Xianyang Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years old; 2. ASA physical status I-II; 3. BMI 18-30 kg/m^2; 4. Patients undergoing gastroscopy under sedation anesthesia at an elective time.

Exclusion criteria

Exclusion criteria: 1. Refusal to sign the informed consent form; 2. Expected difficult airway; 3. Known allergy to the drugs and components used in this study; 4. Known or suspected gastrointestinal obstruction; 5. Acute or severe bronchial asthma; 6. Severe hepatic and renal insufficiency; 7. Long-term use of opioids.

Design outcomes

Primary

MeasureTime frame
ED50 and ED95;

Secondary

MeasureTime frame
Heart rate (HR), oxygen saturation (SpO2), and mean arterial pressure (MAP);Number of airway assistance procedures;Number of endoscopy withdrawals due to persistent hypoxemia;Frequency and duration of dizziness, nausea, and vomiting;Patient and endoscopist satisfaction;Dose of cycloprofen for induction and total administration, dose of tigecycline, time to successful induction, duration of endoscopy (from insertion to removal of endoscope), and use of vasopressor agents;

Countries

China

Contacts

Public ContactWang Yu

Xianyang Central Hospital

13991012233@163.com+86 139 9101 2233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026